


In the Claims:

Please amend claims 1-7 and 9 as follows. Please add new claims 10-12.

1. (Currently Amended) A compound of formula (I):




wherein:

Y is phenyl, substituted with one, two or three substituents selected from
C₁₋₆ alkyl, halosubstitutedC₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, cyano, halo,
C₁₋₆alkylsulfonyl, COOH, halosubstitutedC₁₋₆ alkoxy, CONH₂, NHCOCH₃,
C₁₋₆alkynyl, C₁₋₆alkenyl SO₂NR^{8a}R^{8b} wherein R^{8a} and R^{8b} are
independently selected from H and C₁₋₆alkyl;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and or
 halosubstitutedC₁₋₆ alkyl;

R² is (CH₂)_mR³;

R³ is a ~~an unsubstituted or substituted~~ 5- to 6- membered aromatic heterocycl
 group unsubstituted or substituted with 1, 2 or 3 substituents selected
from C₁₋₆ alkyl, C₁₋₆ alkoxy, halosubstitutedC₁₋₆ alkoxy, halosubstitutedC₁₋₆
alkyl, hydroxy, cyano, halo, sulfonyl, CONH₂ and COOH, or group A:



R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, or halosubstitutedC₁₋₆
 alkyl, COCH₃, and SO₂Me;

R⁶ is unsubstituted or substituted (C₁₋₆)alkyl or chloro and R¹⁰ is hydrogen or R¹⁰
 is unsubstituted or substituted (C₁₋₆)alkyl or chloro and R⁶ is hydrogen
wherein said substituted (C₁₋₆)alkyl is substituted with 1, 2 or 3

substitutents selected from hydroxy, C₁₋₆alkoxy, cyano, halo, NR^{8a} R^{8b}, CONR^{8a}R^{8b}, SO₂NR^{8a}R^{8b}, NR^{8a}COR^{8b} and NR^{8a} SO₂R^{8b},


Ra ~~can be~~ is independently selected from hydrogen, fluoro, chloro and ~~or~~ trifluoromethyl;

Rb ~~can be~~ is independently ~~be~~ selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo substituted C₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH, SO₂CH₃, NHCOCH₃, NHSO₂CH₃ and CONHCH₃;

m is 1 or 2;

or a pharmaceutically acceptable derivative thereof.


2. (Currently Amended) A compound ~~as claimed in claim 1 wherein the compound is~~ of formula (Ia):



wherein

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and ~~or~~ halosubstitutedC₁₋₆ alkyl;

R³ is furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl, tetrazolyl, pyridyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl which can be unsubstituted or substituted with 1, 2 or 3 substitutents selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halosubstitutedC₁₋₆ alkoxy, halosubstitutedC₁₋₆ alkyl, hydroxy, cyano, halo, sulfonyl, CONH₂ and COOH, or R³ is group A:



R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

R⁶ is unsubstituted or substituted (C₁₋₆)alkyl, chloro and R¹⁰ is hydrogen or R¹⁰ is unsubstituted or substituted (C₁₋₆)alkyl or chloro and R⁶ is hydrogen wherein said substituted (C₁₋₆)alkyl is substituted with 1, 2 or 3 substituents selected from hydroxy, C₁₋₆alkoxy, cyano, halo, NR^{8a} R^{8b}, CONR^{8a}R^{8b}, SO₂NR^{8a}R^{8b}, NR^{8a}COR^{8b} and NR^{8a} SO₂R^{8b}.

R_a ~~can be~~ is independently selected from hydrogen, fluoro, chloro and ~~or~~ trifluoromethyl;

R_b ~~can be~~ is independently ~~be~~ selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, halosubstituted C₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH, SO₂CH₃, NHCOCH₃, NHSO₂CH₃ and CONHCH₃;

R¹¹ is C₁₋₆ alkyl, halosubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, cyano, halo, C₁₋₆alkylsulfonyl, CONH₂, NHCOCH₃, COOH, halosubstituted C₁₋₆ alkoxy, C₁₋₆alkynyl, C₁₋₆alkynyl, SO₂NR^{8a}R^{8b};

d is 1, 2, or 3;

m is 1 or 2;

R^{8a} and R^{8b} are independently selected from hydrogen and ~~or~~ C₁₋₆alkyl; or a pharmaceutically acceptable derivative thereof.

3. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~ wherein R¹ is hydrogen or C₁₋₆alkyl

4. (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 3~~ wherein R⁴ is hydrogen or methyl.

5. (Currently Amended) A compound as claimed in claim 1 ~~wherein any preceding claim wherein~~ R³ is selected from group A, pyridinyl, pyrimidinyl, imidazolyl, oxadiazolyl, triazolyl and ~~or~~ pyrazinyl any of which are unsubstituted or substituted with 1, 2 or 3 substituents selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, halosubstituted C₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂ and COOH.

6. (Currently Amended) A compound ~~as claimed in any preceding claim~~ selected from any one of Examples 1 to 79 or a pharmaceutically acceptable derivative thereof.
7. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.~~
8. (Original) A pharmaceutical composition as claimed in claim 7 further comprising a pharmaceutical carrier or diluent thereof.
9. (Currently Amended) A method of treating a ~~human or animal subject~~ mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said mammal ~~subject~~ a therapeutically effective amount of a compound ~~of formula (I)~~ as claimed in claim 1 ~~any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.~~
10. (New) The method as claimed in claim 9, wherein said condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis and osteoporosis
11. (New) The method as claimed in claim 10, wherein said pain is selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.
12. (New) The method as claimed in claim 9, wherein said mammal is a human.